What it sells
Cell-specific genetic medicines
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharmaceutical partners licensing the delivery platform (e.g. Taiho Pharmaceutical).
Economics: what it saves and how it charges
UnverifiedLicenses cell-specific mRNA nanocarrier delivery platform to pharma partners.
Distribution: how it reaches customers
UnverifiedPartnerships and licensing with pharma; Taiho collaboration announced Aug 2024.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.